Johnson & Johnson (JNJ) Could Be 24% Below Fair Value On FDA Approval News
Johnson & Johnson (JNJ) is in focus after the U.S. Food and Drug Administration approved IMAAVY for warm autoimmune hemolytic anemia and after a separate Louisiana jury verdict in a talc related mesothelioma case.
For investors, the latest FDA approval and talc verdict land against a backdrop of strong momentum in Johnson & Johnson’s stock, with a 30 day share price return of 8.18% and a 90 day share price return of 20.62% contributing to a 1 year total shareholder return of 58.10%. This suggests sentiment has been improving even as legal and pipeline headlines continue to shape perceptions of future growth and risk.
Compare Johnson & Johnson’s momentum and risk profile with a curated 75 resilient stocks with low risk scores that share resilient characteristics, even as headlines swing between drug approvals and courtroom outcomes.
After a 58.10% total return in 1 year and a recent FDA win, Johnson & Johnson now trades only a fraction below published price targets. Is most of the rerating already in the rear-view mirror, or does valuation still leave meaningful upside?
Most Popular Narrative: 1.7% Overvalued
Johnson & Johnson closed at $275.21, a touch above the most followed fair value estimate of $270.59 that applies a 7.11% discount rate and long term earnings assumptions.
The analysts have a consensus price target of $270.59 for Johnson & Johnson based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $305.0, and the most bearish reporting a price target of just $190.0.
Analysts reference steady revenue expansion, rising margins, and a rich future earnings multiple in their assumptions. This raises questions about which assumptions are most influential in that fair value estimate.
Result: Fair Value of $270.59 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in Johnson & Johnson still need to weigh talc litigation outcomes and potential pressure from drug price policy, as both could challenge the current narrative.
Find out about the key risks to this Johnson & Johnson narrative.
Another View on Johnson & Johnson’s Valuation
Analyst targets suggest Johnson & Johnson is only about 1.7% above the most followed fair value estimate, yet our DCF model points to a different picture. In that framework, JNJ trades about 24.4% below an estimated future cash flow value of $364.27. Which lens do you rely on more for your next decision?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Given the mix of optimism and concern around Johnson & Johnson, it makes sense to check the underlying data yourself and move quickly to shape your own view. To see how the potential upside and downside stack up in one place, review the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Johnson & Johnson?
If Johnson & Johnson has sharpened your focus on quality and risk, do not stop here. Use targeted stock lists to widen your watchlist with purpose.
- Spot potential value opportunities early by scanning a focused group of companies that appear mispriced on fundamentals using the 54 high quality undervalued stocks.
- Strengthen your income stream by reviewing a curated set of stocks with higher yields and resilient profiles through the 11 dividend fortresses.
- Prioritise resilience by checking a carefully filtered list of solid balance sheet and fundamentals (52 results) that can help anchor your portfolio when sentiment swings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com